Glycans in Drug Design

Glycans are components of many bio-therapeutic agents, ranging from natural products to molecules based on rational design to recombinant glycoproteins. The glycan components of these agents can be important determinants of their biological activity and therapeutic efficacy. Biochemistry and Glycobiology involves a multidisciplinary study of carbohydrate-binding proteins (lectins), glycolipids  and some other plant proteins that are capable of interacting with endogenous or foreign (macro) molecules. The emphasis of the research is on protein-carbohydrate interaction and their involvement in signalling processes in plants or in plant protection. Based on the generated fundamental knowledge novel strategies are being developed to protect crop plants against pests and diseases.

Relevant Conferences: Glycobiology Conferences Biochemistry Conferences

7th International Conference on Bioinformatics, October 24-26, 2016 Rome, Italy; International Conference on Structural Biology, August 22-23, 2016 New Orleans, USA; International Conference on Glycomics, December 01-02, 2016 Atlanta, Georgia, USA; International Conference on Nucleic Acids, August 04-05, 2016 New Orleans, Louisiana, USA; 2nd International Conference on Transcriptomics, September 12-14, 2016 Philadelphia, Pennsylvania, USA; International Conference on Obesity & Chronic Diseases, July 25-27, 2016 Las Vegas USA; International Conference on New Therapeutics for Diabetes and Obesity, April 17-20, 2016 La Jolla, USA; Conference on Plasma Spectrochemistry, January 10-16, 2016 Tucson, USA; Euro Fed Lipid Congress, September 18-21, 2016 Gent, Belgium; Conference on Obesity and Adipose Tissue Biology, February 15-19, 2016 Banff, Canada; Society for Glycobiology, November 19-22, 2016 New Orleans, Louisiana, USA; American Society for Biochemistry and Molecular Biology (ASBMB), April 02-06, 2016 San Diego, USA; Federation of American Societies for Experimental Biology (FASEB), June 12-17, 2016 Florida, USA

Biotherapeutic protein producers have taken pains to ensure consistency in glycosylation of recombinant therapeutic proteins, mostly due to the potential immunogenic properties of non-self glycans, the impact of glycosylation pharmacokinetics, and glycan in vivo functionality. Changes in glycosylation are often a hallmark of disease states. In the past decade advances in genomics, proteomics and mass spectrometry have enabled the association of specific glycan structures with disease states. In some cases the functional significance of disease-associated changes in glycosylation has been revealed. This highlights changes in glycosylation associated with cancer and chronic inflammation and new therapeutic and diagnostic strategies that are based on the underlying glycobiology. 

  • Drug interaction in cellular networking
  • Proteome mapping
  • Biomarkers in drug design
  • Protein–ligand and protein–protein interactions
  • Screening and drug design
  • Drug delivery using Nanotechnology

Related Conference of Glycans in Drug Design

September 18-20, 2017

9th International Conference on Structural Biology

Zurich, Switzerland
September 21-22, 2017

International Conference on Glycobiology

Houston, Texas, USA
September 28-29, 2017

2nd International Conference on Biochemistry

Dubai, UAE
October 25-26, 2017

Global Proteomics Conference

Dubai, UAE
October 30 - November 01, 2017

3rd International Conference on Transcriptomics

Bangkok, Thailand
November 13-15, 2017

9th International Conference and Expo on Proteomics

Paris, France
November 13-14, 2017

9th International Conference on Bioinformatics

Paris, France
February 19-20, 2018

EuroSciCon Conference on Chemistry

Paris, France

Glycans in Drug Design Conference Speakers

Recommended Sessions

Related Journals

Are you interested in